Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Comment by M101on Jul 16, 2021 7:20pm
84 Views
Post# 33564324

RE:Incoming . Hopefully not 8 cents again

RE:Incoming . Hopefully not 8 cents again LMAO, how about this version at Politico: 

"INFLUENTIAL DRUG PRICING PANEL SEES NO BENEFIT FROM ADUHELM — An expert panel convened by the Institute for Clinical and Economic Review concluded Thursday that the controversial Alzheimer's drug does not work better than existing forms of care — and isn’t worth Biogen’s $56,000 price tag. The group rendered its verdict as a unanimous vote at a meeting reviewing Aduhelm, which FDA approved last month.

“Looking at the data, if I had to guess, the data is stronger for net harm than it is for net benefit,” said Sai Lee, a geriatrician at the University of California San Francisco and one of 15 voting members of Thursday’s panel.

Though ICER can’t determine drug prices, it can influence lawmakers and other stakeholders who do. Currently, CMS is meeting to discuss whether Medicare will cover the drug.

<< Previous
Bullboard Posts
Next >>